Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose provides caloric supplementation and serves as a source of glucose for cellular metabolism. Sodium chloride provides electrolytes for maintenance of fluid and electrolyte balance.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Parenteral replenishment of fluid and calories in patients unable to take adequate oral intake,Correction of fluid and electrolyte imbalances,As a vehicle for intravenous drug administration
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Intravenous infusion; typical adult dose is 1000-2000 m L per day, rate dependent on clinical condition and fluid status; maximum infusion rate usually 5 m L/kg/hour.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Dextrose has a plasma half-life of approximately 1-2 hours; sodium and chloride have half-lives that depend on renal function and hydration status, typically 6-12 hours for sodium. In clinical context, half-life is not typically used for fluid and electrolyte replacement.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Dextrose is metabolized via glycolysis and the citric acid cycle; sodium chloride is not metabolized.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Dextrose and sodium chloride are endogenous substances. Dextrose is metabolized to CO2 and water; excess is excreted renally as glucose. Sodium and chloride are primarily excreted renally, with minimal biliary/fecal elimination. Nearly 100% of infused sodium and chloride are eliminated renally under normal conditions.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Dextrose: negligible (<1%). Sodium: negligible. Chloride: negligible.
Low protein binding; 0–11% bound, primarily to albumin.
Dextrose: approximately 0.2 L/kg (extracellular fluid). Sodium: 0.2 L/kg (extracellular fluid). Chloride: 0.2 L/kg (extracellular fluid). These reflect distribution primarily in extracellular space.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Intravenous: 100%.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
e GFR <30 m L/min: Use with caution; monitor fluid and electrolyte balance; adjust volume and rate based on renal function and urine output.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No specific adjustment required; use caution in severe hepatic impairment due to potential volume overload.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Weight-based: Initial dose 5-10 m L/kg, may repeat as needed; maintenance: 80-120 m L/kg/day for infants and 60-80 m L/kg/day for older children; adjust rate based on clinical response and glucose/electrolyte monitoring.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Start at lower end of adult dose; monitor for fluid overload, hyperglycemia, and electrolyte disturbances due to decreased renal function and cardiovascular reserve.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
None
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Risk of hyperglycemia, especially in patients with diabetes mellitus or impaired glucose tolerance,Risk of fluid overload, particularly in patients with cardiac or renal impairment,Electrolyte imbalances with prolonged use or rapid infusion,May cause phlebitis or extravasation at infusion site,Use with caution in patients with intracranial or intraspinal hemorrhage
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hyperglycemia (severe) or diabetic coma with hyperglycemia,Hypersensitivity to any component,Clinically significant hypernatremia or fluid overload,Patients with increased intracranial pressure
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No specific food interactions. However, due to dextrose content, patients with diabetes should monitor blood glucose closely. Avoid concurrent use with alcohol due to risk of hypoglycemia or hyperglycemia.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
First trimester: No evidence of teratogenicity from dextrose or sodium chloride at recommended doses. Second and third trimesters: Use is generally safe; however, administration of large volumes may cause electrolyte imbalances and fluid overload, potentially affecting fetal hydration status.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Both dextrose and sodium chloride are endogenous substances and are present in breast milk at concentrations similar to maternal plasma. M/P ratio: Not applicable; considered compatible with breastfeeding.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
No dose adjustments required for standard maintenance fluids. However, pregnant patients may have increased volume of distribution and renal clearance; monitor for fluid and electrolyte balance, and adjust infusion rate accordingly to prevent overload.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Contains 10% dextrose (100 g/L) and 0.2% sodium chloride (34 m Eq/L Na+ and Cl-). Osmolality approximately 505 m Osm/L, p H ~4.0. Provides 340 kcal/L. Use with caution in patients with fluid overload, heart failure, or renal impairment. Monitor serum glucose, electrolytes, and fluid balance. Not for use as a sole source of nutrition; consider thiamine supplementation in chronic alcoholics to prevent Wernicke's encephalopathy. Do not administer with blood products through same IV line.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
This solution provides sugar (dextrose) and salt (sodium chloride) to help maintain your body's fluid and energy balance.,Report any signs of allergic reaction, such as rash, itching, or difficulty breathing, during infusion.,Inform your healthcare provider if you have diabetes, high blood pressure, heart failure, or kidney disease.,This solution is given through a vein; you may feel warmth or discomfort at the injection site.,Follow your doctor's instructions regarding fluid intake and monitoring of blood sugar levels.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose provides caloric supplementation and serves as a source of glucose for cellular metabolism. Sodium chloride provides electrolytes for maintenance of fluid and electrolyte balance.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 1000-2000 m L per day, rate dependent on clinical condition and fluid status; maximum infusion rate usually 5 m L/kg/hour.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is classified as Category A/B. First trimester: No evidence of teratogenicity from dextrose or sodium chloride at recommended doses. Second and third trimesters: Use is generally safe; however, administration of. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.